Intellia Therapeutics Inc
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$19.00 | Wvxy | Fgmmhnfs |
Intellia Earnings: Gene Editing Pipeline Continues to Make Progress; Shares Very Undervalued
Intellia Therapeutics reported first-quarter results in line with our expectations, and its pipeline candidates are continuing to make progress. Collaboration revenue totaled $12.6 million for the quarter, representing a 12% increase from the prior year period. Intellia ended the quarter in a healthy financial position with about $1.2 billion in cash, which will help fund its research and development expenses as it develops its pipeline candidates. We maintain our positive outlook and fair value estimate of $85 per share. We view the stock as very undervalued, currently trading in 5-star territory.